A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.

Rojas, J J; Cascallo, M; Guedan, S; Gros, A; Martinez-Quintanilla, J; Hemminki, A; Alemany, R

Rojas, J J; Cascallo, M; Guedan, S; Gros, A; Martinez-Quintanilla, J; Hemminki, A; Alemany, R.

Affiliation

Rojas JJ; Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.

Gene Ther ; 16(12): 1441-51, 2009 Dec.

Article in En | MEDLINE | ID: mdl-19710704

Subject(s)

Adenoviridae/genetics; Adenovirus E1A Proteins/biosynthesis; E2F1 Transcription Factor/genetics; Oncolytic Viruses/genetics; Promoter Regions, Genetic; Animals; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Viral; Humans; Male; Mice; Mice, Nude; Oncolytic Virotherapy/methods; Virus Replication

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenoviridae / Promoter Regions, Genetic / Adenovirus E1A Proteins / Oncolytic Viruses / E2F1 Transcription Factor Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Gene Ther Journal subject: GENETICA MEDICA / TERAPEUTICA Year: 2009 Document type: Article Affiliation country: Spain Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google